Mabwell
Biopharmaceutical company developing monoclonal antibodies, antibody-drug conjugates and biosimilars.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Advanced Urothelial Carcinoma
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerPhase 3 · Recruiting · Urothelial Carcinoma
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerPhase 3 · Recruiting · Cervical Cancer
A Clinical Study of 9MW2821 in Advanced Malignant Solid TumorsPhase 1 · Recruiting · Advanced Malignant Solid Tumors
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraPhase 1 · Recruiting · Polycythemia Vera
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaPhase 2 · Recruiting · Urothelial Carcinoma
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/mabwell/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.